MONTREAL, Sept. 7, 2023 /CNW/ - Innodem Neurosciences, a leading digital health and AI company, announced today that it has signed a multimillion, multi-year Commercial Framework Agreement with Novartis Pharmaceuticals Canada Inc. (Novartis)...
News & events
Oculomotor analysis to assess brain health: preliminary findings from a longitudinal study of multiple sclerosis using novel tablet-based eye-tracking software
A growing body of evidence supports the link between eye movement anomalies and brain health. Indeed, the oculomotor system is composed of a diverse network of cortical and subcortical structures and circuits that are susceptible to a variety of degenerative...
A novel tablet-based software for the acquisition and analysis of gaze and eye movement parameters: a preliminary validation study in Parkinson’s disease
The idea that eye movements can reflect certain aspects of brain function and inform on the presence of neurodegeneration is not a new one. Indeed, a growing body of research has shown that several neurodegenerative disorders, such as Alzheimer’s and Parkinson’s...
ETNA™ Device from Leading Digital Health & AI Company Innodem Neurosciences Receives FDA “Breakthrough” Designation for Multiple Sclerosis
MONTREAL, May 31, 2022 /CNW Telbec/ - Innodem Neurosciences, a leading provider of innovation and technology for the convergence of neurosciences, digital health, pharmaceutical and artificial intelligence, is proud to announce that its novel mobile eye...
Innodem Neurosciences Signs a Strategic Partnership with Novartis Pharmaceuticals Canada Inc.
MONTREAL, Oct. 5, 2021 /PRNewswire/ - Innodem Neurosciences announced today that it has signed a multi-year partnership agreement with Novartis Pharmaceuticals Canada Inc. (Novartis) to conduct a breakthrough clinical trial to help people living with...
Innodem Neurosciences receives 6 million US Dollars of financing from Morningside Group
Innodem Neurosciences, a Montreal-based company, has closed a Series A financing round led by Morningside Ventures to support the development and commercialization of its proprietary, patented, digital biomarking technology of neurodegenerative diseases such as...
Innodem launches Pigio™ on the App store
Patients who have lost the use of speech will soon be able to communicate with their eyes thanks to a mobile application developed in Quebec. Called Pigio™, the application will allow communication with the eyes, which act as a cursor on a digital screen. "You have...
Innodem raises $1M in angel financing
Montreal-based Innodem Neurosciences has received $1 million from angel, banking, and government entities to begin commercializing Pigio™, its first mobile app. Pigio™ uses AI-powered mobile software technology to allow paralyzed or intubated patients to communicate...
World Economic Forum – Dr. Etienne de Villers-Sidani speaks in Tianjin, China
Dr. de Villers-Sidani was amongst the three McGill researchers presented their work to the World Economic Forum’s (WEF) Annual Meeting of the New Champions (a.k.a. “Summer Davos”) on September 18, in Tianjin, China. It’s the foremost global summit on...
Innodem wins Centech Propulsion Program
CENTECH, a Montreal-based technology incubator, announced earlier that it has selected a company founded by Dr. Etienne de Villers-Sidani for its Propulsion Program, which helps the most innovative start-ups move from the initial development phase to commercializing...